Bioequivalence evaluation of Florfenicol pharmaceutics in pigs using liquid chromatography-tandem mass spectrometry.

The bioequivalence of two Florfenicol (FF) products in pigs was evaluated. A 2 × 2 crossover trial with a 14 days wash-out period was performed. The pigs were orally administered in a single dose (2 mg/kg b.w of FF). Serum samples were analyzed using a liquid chromatography-tandem mass spectrometry method. The limit of quantification was 0.1 ng/mL, and the calibration range was 1.0-100.0 ng/mL. Furthermore, intraday and interday were 5.43-9.09% and 6.23-9.68%, respectively. The areas under the curve (AUC0-48) for the test product B of FF and reference product A were 7289.61 ± 1750.44 and 6545.01 ± 2766.25 h × ng/mL, respectively. The highest concentrations of FF in the serum (Cmax) were 726.05 ± 211.77 and 641.97 ± 117.94 ng/mL. The mean retention times (MRT) was 7.91 ± 1.98 and 7.76 ± 2.89 h while the half-lives (T1/2) were 4.07 ± 1.71 and 4.99 ± 3.30 h. From the analysis of variance results, the p values of Cmax and AUC0-∞ for the 90% confidence interval were 0.492 and 0.320 (p > 0.05), respectively. A comparison between the test product and the reference product showed no significant difference. Both products showed bioequivalence after being administered in pigs. [ABSTRACT FROM AUTHOR]